Giovanni Caforio (Photographer: Christopher Goodney/Bloomberg via Getty Images)
May 20, 2021 10:20 AM EDT
R&D
Pharma

#AS­CO21: Bris­tol My­ers takes home the win in 1st late-stage study for LAG-3 path­way, set­ting up a US fil­ing

Kyle Blankenship

When Bris­tol My­ers Squibb dropped win­ning late-stage da­ta for its an­ti-LAG-3 drug in March, the re­sults of­fered new hope for an im­mune check­point path­way that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times